Reviewing Nyxoah (NASDAQ:NYXH) and KORU Medical Systems (NASDAQ:KRMD)

KORU Medical Systems (NASDAQ:KRMD) and Nyxoah (NASDAQ:NYXH) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Valuation and Earnings

This table compares KORU Medical Systems and Nyxoah”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KORU Medical Systems	$33.65 million	6.39	-$6.07 million	($0.08)	-58.00
Nyxoah	$4.89 million	25.91	-$64.10 million	($2.49)	-1.49

KORU Medical Systems has higher revenue and earnings than Nyxoah. KORU Medical Systems is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations for KORU Medical Systems and Nyxoah, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KORU Medical Systems	1	1	3	1	2.67
Nyxoah	1	0	3	1	2.80

KORU Medical Systems currently has a consensus target price of $6.13, indicating a potential upside of 32.00%. Nyxoah has a consensus target price of $11.67, indicating a potential upside of 213.62%. Given Nyxoah’s stronger consensus rating and higher probable upside, analysts plainly believe Nyxoah is more favorable than KORU Medical Systems.

Risk and Volatility

KORU Medical Systems has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.56, indicating that its stock price is 56% more volatile than the S&P 500.

Profitability

This table compares KORU Medical Systems and Nyxoah’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
KORU Medical Systems	-9.49%	-22.43%	-13.86%
Nyxoah	-1,457.97%	-101.99%	-66.74%

Insider & Institutional Ownership

58.6% of KORU Medical Systems shares are owned by institutional investors. 20.6% of KORU Medical Systems shares are owned by insiders. Comparatively, 17.1% of Nyxoah shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

KORU Medical Systems beats Nyxoah on 8 of the 13 factors compared between the two stocks.

About KORU Medical Systems

KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.